Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 704-712

  Sun, Yifeng ^a   Su, Bo ^a   Zhang, Peng ^a   Xie, Huikang ^a   Zheng, Hui ^a   Xu, Yongjie ^a   Du, Qiaoling ^a   Zeng, Huan ^a   Zhou, Xiao ^a   Chen, Chang ^a   Gao, Wen ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI CHEST HOSPITAL   (China)

Author keywords

Clinicopathology; MicroRNAs; Non small cell lung carcinoma; Quantitative RT PCR

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; KI 67 ANTIGEN; MICRORNA; MICRORNA 150; MICRORNA 18B-5P; MICRORNA 3940-5P; MICRORNA 643; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CELL DEDIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; TUMOR GROWTH;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; FEMALE; HUMANS; KI-67 ANTIGEN; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872812457     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2152     Document Type: Article

References (35)

1. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
2. Eder M and Scherr M: MicroRNA and lung cancer. N Engl J Med 352: 2446-2448, 2005. (Pubitemid 40958446)
3. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS and Benz CC: Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 282: 1479-1486, 2007. (Pubitemid 47076526)
4. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006. (Pubitemid 44629897)
5. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007. (Pubitemid 46148091)
6. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol 2: 706-714, 2007. (Pubitemid 47357522)
7. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24: 4539-4544, 2006. (Pubitemid 46630948)
8. Takamizawa J, Konishi H, Yanagisawa K, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756, 2004. (Pubitemid 38697282)
9. Yu SL, Chen HY, Chang GC, et al: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48-57, 2008.
10. Raponi M, Dossey L, Jatkoe T, et al: MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 69: 5776-5783, 2009.
11. Soomro IN, Holmes J and Whimster WF: Predicting prognosis in lung cancer: use of proliferation marker, Ki67 monoclonal antibody. J Pak Med Assoc 48: 66-69, 1998. (Pubitemid 128705640)
12. Tiscornia G and Izpisua Belmonte JC: MicroRNAs in embryonic stem cell function and fate. Genes Dev 24: 2732-2741, 2010.
13. Monzo M, Navarro A, Bandres E, et al: Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res 18: 823-833, 2008.
14. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000. (Pubitemid 30054364)
15. Takahashi S, Kamata Y, Tamo W, et al: Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases. Int J Clin Oncol 7: 349-355, 2002. (Pubitemid 36077317)
16. Martin B, Paesmans M, Mascaux C, et al: Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91: 2018-2025, 2004. (Pubitemid 40128768)
17. Woo T, Okudela K, Yazawa T, et al: Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer 65: 355-362, 2009.
18. Watanabe A, Tagawa H, Yamashita J, et al: The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia 25: 1324-1334, 2011.
19. Ma Y, Zhang P, Wang F, et al: miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut 61: 1447-1453, 2011.
20. Toyooka S, Matsuo K, Shigematsu H, et al: The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non-small cell lung cancer. Clin Cancer Res 13: 5763-5768, 2007. (Pubitemid 47583901)
21. Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM and De Flora S: Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J 23: 806-812, 2009.
22. Liao JY, Ma LM, Guo YH, et al: Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of miRNAs and tRNA 3' trailers. PLoS One 5: e10563, 2010.
23. Persson H, Kvist A, Rego N, et al: Identification of new micro RNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 71: 78-86, 2011.
24. Starzynska T, Bromley M, Ghosh A and Stern PL: Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66: 558-562, 1992.
25. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L and Borresen AL: Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68: 540-548, 1993. (Pubitemid 23258459)
26. Chava S, Mohan V, Shetty PJ, et al: Immunohistochemical evaluation of p53, FHIT, and IGF2 gene expression in esophageal cancer. Dis Esophagus 25: 81-87, 2012.
27. Yamakuchi M, Ferlito M and Lowenstein CJ: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 105: 13421-13426, 2008.
28. Park SY, Lee JH, Ha M, Nam JW and Kim VN: miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 16: 23-29, 2009.
29. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973-982, 2001. (Pubitemid 34428742)
30. Fornari F, Gramantieri L, Giovannini C, et al: MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 69: 5761-5767, 2009.
31. Laurent LC, Chen J, Ulitsky I, et al: Comprehensive microRNA profiling reveals a unique human embryonic stem cell signature dominated by a single seed sequence. Stem Cells 26: 1506-1516, 2008.
32. Ren J, Jin P, Wang E, Marincola FM and Stroncek DF: MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med 7: 20, 2009.
33. Zhao C, Sun G, Li S, et al: MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. Proc Natl Acad Sci USA 107: 1876-1881, 2010.
34. Melton C, Judson RL and Blelloch R: Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature 463: 621-626, 2010.
35. Yu F, Yao H, Zhu P, et al: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123, 2007. (Pubitemid 350235025)